Study of CMP-CPS-001 in Healthy Volunteers and Participants With Abnormal Heterozygous OTC Genotype

Phase 1 Active not recruiting 120 enrolled CAMP4 Therapeutics Corporation

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of CMP-CPS-001 administered as a subcutaneous injection in adult healthy volunteers and participants with abnormal heterozygous OTC genotype.

Timeline

Start: 2024-02-05
Primary completion: 2027-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CMP-CPS-001	Antisense oligonucleotide	—	Subcutaneous

Study of CMP-CPS-001 in Healthy Volunteers and Participants With Abnormal Heterozygous OTC Genotype

Summary

Timeline

Drugs

Indications